768 related articles for article (PubMed ID: 9289394)
1. Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study.
Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
Hum Antibodies; 1997; 8(2):95-8. PubMed ID: 9289394
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
3. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
Reid I; Lundy J; Donohue JH
J Immunol; 1992 Apr; 148(8):2630-5. PubMed ID: 1532818
[TBL] [Abstract][Full Text] [Related]
5. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.
Hardy B; Yampolski I; Kovjazin R; Galli M; Novogrodsky A
Cancer Res; 1994 Nov; 54(22):5793-6. PubMed ID: 7954401
[TBL] [Abstract][Full Text] [Related]
6. In vivo administration of anti-CD3 monoclonal antibody can activate immune responses thus preventing malignant tumor growth.
Hirsch R; Ellenhorn JD; Bluestone JA
Princess Takamatsu Symp; 1988; 19():237-43. PubMed ID: 2978618
[TBL] [Abstract][Full Text] [Related]
7. BAT mAb induces lymphopoiesis in nude mice.
Hardy B; Niv Y; Fadaeev L; Raiter A
Int Immunol; 2005 May; 17(5):615-9. PubMed ID: 15802304
[TBL] [Abstract][Full Text] [Related]
8. [T lymphocyte activation induced by monoclonal anti-CD3 antibodies: physiopathology of cytokine release].
Chatenoud L; Bach JF
C R Seances Soc Biol Fil; 1991; 185(5):268-77. PubMed ID: 1806186
[TBL] [Abstract][Full Text] [Related]
9. Cancer disease predictive diagnosis: BAT/CD3-positive lymphocytes in cancer patients.
Hardy B; Raiter A; Rubin M; Sprecher E; Sella A; Flex D; Lelcuk S; Bsharah B; Mishaeli M; Niv Y
Int J Oncol; 2005 Apr; 26(4):971-5. PubMed ID: 15753991
[TBL] [Abstract][Full Text] [Related]
10. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
11. The antitumor activity induced by the in vivo administration of activated B cells bound to anti-CD3 monoclonal antibody.
Harada M; Okamoto T; Kurosawa S; Shinomiya Y; Ito O; Takenoyama M; Terao H; Matsuzaki G; Kimura G; Nomoto K
Cell Immunol; 1995 Mar; 161(1):132-7. PubMed ID: 7867078
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
13. Activation of lymphocytes by BAT and anti CTLA-4: comparison of binding to T and B cells.
Raiter A; Novogrodsky A; Hardy B
Immunol Lett; 1999 Aug; 69(2):247-51. PubMed ID: 10482359
[TBL] [Abstract][Full Text] [Related]
14. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
15. In vivo T cell activation properties of anti-T cell monoclonal antibodies.
Ferran C; Bach JF; Chatenoud L
Exp Nephrol; 1993; 1(2):83-9. PubMed ID: 8081961
[TBL] [Abstract][Full Text] [Related]
16. Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein.
Hardy B; Galli M; Rivlin E; Goren L; Novogrodsky A
Cancer Immunol Immunother; 1995 Jun; 40(6):376-82. PubMed ID: 7627994
[TBL] [Abstract][Full Text] [Related]
17. Fas cross-linking mimics the inhibitory effect of anti-CD3 on IL-3-induced histamine and cytokine production by murine myeloid spleen cell precursors.
Ben Amor A; Schneider E; Arnould A; Machavoine F; Dy M
Exp Hematol; 1998 Aug; 26(9):903-9. PubMed ID: 9694512
[TBL] [Abstract][Full Text] [Related]
18. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
Seo N; Tokura Y; Takigawa M; Egawa K
J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
[TBL] [Abstract][Full Text] [Related]
19. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
20. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]